Clinical Trial: Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07415005) titled 'Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer' on Feb. 13.

Brief Summary: This is an open-label, multicenter, randomized phase 2 trial for patients with tyrosine kinase inhibitor-naive ALKrearranged advanced NSCLC. Subjects are initially treated with lorlatinib for 12 weeks.

Study Start Date: Aug. 31, 2026

Study Type: INTERVENTIONAL

Condition: Advanced Non-Small Cell Lung Cancer

Intervention: DRUG: Lorlatinib

Given Orally

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M.D. Anderson Cancer Center

Published by HT Digital Content Services with permission from Health Daily Dig...